ORAGENICS INC — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
On August 26, 2026, Oragenics received a NYSE American deficiency letter for failing continued listing standards (stockholders' equity requirement: $4M if three of four years reported losses, or $6M if five consecutive years reported losses). The company has 45 days to submit a compliance plan and until February 25, 2028 to regain compliance. Operationally, the company has dosed 9 participants in its Australia-based Phase IIa trial of ONP-002 for mTBI across three active sites and expects to submit a U.S. IND application by end of 2026.
Why this rating
Delisting threat is business-critical for $3.1M market-cap company. Reputational and operational damage from exchange removal could impair financing, partnerships, and clinical recruitment—existential risk. Clinical progress is modest and expected; regulatory momentum is offset by listing jeopardy.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.